屈大麻酚(Dronabinol) - 药物靶点：CB_在研适应症：厌食症，恶心，呕吐_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(-)-delta9-trans-Tetrahydrocannabinol、1-trans-delta-9-Tetrahydrocannabinol、3-Pentyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-dibenzo(b,d)pyran-1-ol

+ [40]

靶点

CB

作用方式

激动剂

作用机制

CB激动剂(大麻素受体激动剂)

治疗领域

其他疾病神经系统疾病消化系统疾病+ [5]

在研适应症

厌食症恶心呕吐+ [13]

非在研适应症

抑郁症多发性硬化症Tourette 综合征

原研机构

AbbVie, Inc.

在研机构

Spaulding Clinical Research LLC

Avicanna, Inc.

Tetra Bio-Pharma, Inc.

+ [8]

非在研机构

Unimed Pharmaceutical, Inc.

Benuvia, Inc.

SciSparc Ltd.

+ [1]

权益机构

IntelGenx Corp.

Alkem Laboratories Ltd.

DanCann Pharma A/S

+ [6]

最高研发阶段批准上市

首次获批日期

美国 (1985-05-31),

厌食症恶心呕吐

最高研发阶段(中国)-

特殊审评突破性疗法 (美国)、孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C21H30O2

InChIKeyCYQFCXCEBYINGO-IAGOWNOFSA-N

CAS号1972-08-3

关联

368

项与屈大麻酚相关的临床试验

ACTRN12620000847910

/ Not yet recruiting临床1/2期

Safety and Effect of Medical Cannabis on Relapse among 20 Patients with Methamphetamine Use Disorder: A Proof-of-Concept Trial

开始日期2026-12-01

申办/合作机构

University of Edith Cowan

NCT07148206

/ Not yet recruiting临床3期IIT

Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial

The goal of this pilot study is to test novel, adjunctive pharmacotherapy for patients with opioid use disorder (POUD) who may be at risk for overdose and other poor opioid use disorder (OUD) outcomes even after initiating buprenorphine. The investigator team proposes to test the effectiveness of combined dronabinol (synthetic delta-9-tetrahydrocannabinol [THC]) and Epidiolex (cannabidiol [CBD]) - two FDA-approved cannabinoids - to improve retention in buprenorphine treatment and reduce opioid use among POUD who are early in treatment. POUD who are early in treatment are at a critical juncture-a moment of opportunity and motivation, but also of high risk of return to opioid use and loss to follow up.

开始日期2026-10-01

申办/合作机构

Montefiore Medical Center

[+1]

NCT06956014

/ Not yet recruiting临床3期

Multicenter, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of the Full-spectrum Cannabis Extract VER-01 in Patients With Radicular Chronic Low Back Pain

The aim of the trial is to prove the efficacy and safety of VER-01 corresponding to 22.5 mg or 32.5 mg THC compared to placebo in patients with chronic low back pain (CLBP) with a radicular component for whom drug treatment is indicated and previous optimized treatments with non-opioid analgesics have not led to sufficient pain relief or were unsuitable due to contraindications or intolerance.

开始日期2026-09-01

申办/合作机构

Vertanical GmbH

100 项与屈大麻酚相关的临床结果

登录后查看更多信息

100 项与屈大麻酚相关的转化医学

登录后查看更多信息

100 项与屈大麻酚相关的专利（医药）

登录后查看更多信息

12,217

项与屈大麻酚相关的文献（医药）

2026-12-31·PLATELETS

Pilot study on cannabis-induced alterations in platelet function: implications for transfusion medicine

Article

作者: Loubaki, Lionel ; Cognasse, Fabrice ; Hamzeh-Cognasse, Hind ; Laflamme, Geneviève

Platelet transfusions are essential in the management of thrombocytopenia, bleeding disorders, and hematologic malignancies. With cannabis use rising worldwide, its impact on donor platelet quality and transfusion efficacy remains poorly understood. This study investigated the effects of cannabis joint extracts (CJE) on platelet activation, pro-coagulant phenotype, mitochondrial function, and cytokine/chemokine release, with implications for transfusion safety. Human platelets were exposed in vitro to increasing concentrations of two CJE with distinct cannabinoid profiles: Orchid (O-CJE, THC 10.4%, CBD 14.7%) and QCGold (G-CJE, THC 25.5%, CBD 0.04%). Platelet activation (CD62P, Annexin V), mitochondrial depolarization, ATP levels, aggregation responses, and cytokine secretion (CCL3, PF4) were assessed. RBC lysate experiments were performed to assess the role of hemolysis. The involvement of CB1 and CB2 receptors was tested using specific antagonists, and activation of p38 MAPK and NF-κB pathways was evaluated. Functional effects of platelet supernatants were examined on EA.hy926 endothelial cells. CJE exposure induced dose-dependent platelet activation, characterized by increased CD62P expression, Annexin V binding, mitochondrial depolarization, and ATP depletion, consistent with metabolic stress. Platelet aggregation in response to ADP, collagen, and arachidonic acid was impaired, suggesting a pre-activated or refractory phenotype. RBC lysate did not reproduce the observed effects, indicating hemolysis is unlikely to be the underlying mechanism. CBR1 and CBR2 antagonists did not attenuate platelet activation, while signaling analysis revealed activation of p38 MAPK and NF-κB pathways. Exploratory proteomics indicated modulation of proteins involved in angiogenesis, cytoskeletal organization, and stress responses. Elevated plasma levels of CCL3 and PF4 and endothelial activation (IL-6 secretion, CD54, CD62P, CD62E expression) further suggested a pro-inflammatory environment. Cannabis exposure can alter platelet phenotype and signaling under in vitro conditions, potentially affecting platelet function and interactions with the vascular endothelium. However, these findings require confirmation in vivo to determine their clinical relevance. Future studies should aim to establish exposure thresholds and clarify whether cannabis use has implications for transfusion safety, given potential risks of reduced efficacy or increased thrombotic complications in recipients.

2026-10-01·NEUROBIOLOGY OF AGING

Effects of sub-chronic cannabis smoke exposure on inflammatory markers in serum and brain in younger and older mice

Article

作者: Krumm, Zachary A ; Setlow, Barry ; Zequeira, Sabrina ; Bizon, Jennifer L ; Gazarov, Emely A ; McCracken, Bailey

Aging is associated with chronic low-grade inflammation, which is thought to contribute to both cognitive decline and various neurodegenerative diseases. Cannabinoids are reported to reduce levels of inflammatory markers; however, these effects have not been thoroughly assessed in older subjects. To address this gap, we evaluated the effects of sub-chronic cannabis smoke exposure on serum and brain inflammatory markers in younger and older mice. Younger (4 month old) and older (22 month old) C57Bl/6J mice were exposed to smoke from burning either cannabis (5.5-6.2% THC) or placebo (0% THC) cigarettes daily for 30 consecutive days. Following exposure sessions, both blood and brain tissue from the prefrontal cortex (PFC) and hippocampus (HPC) were collected and analyzed for multiple markers of inflammation. Overall, the patterns of inflammatory markers varied across serum, PFC, and HPC. Both comparisons of individual cytokines and global cytokine profiles revealed that aging caused increases in cytokine levels in all three sample types. Global cytokine analysis showed increases in PFC inflammatory markers in younger and older mice exposed to cannabis smoke. In contrast, HPC samples had significant Age x Drug interactions, such that cannabis smoke exposure tended to increase cytokine levels in younger mice but decrease them in older mice. These findings point to general age-related increases in serum and brain inflammatory markers in this mouse strain; however, age-dependent cannabis effects were largely restricted to the HPC.

2026-09-01·CLINICA CHIMICA ACTA

Direct-to-definitive urine drug screening in children unmasks false-negative immunoassay screening

Article

作者: Patel, Khushbu ; Lin, Yanchun ; Roper, Stephen M ; Garg, Uttam C ; El-Khoury, Joe M ; Jones, Patricia M ; Dietzen, Dennis J ; Lo, Stanley F

BACKGROUND:

Routine urine drug screening is performed using immunoassays. False-positive immunoassay results are well documented and confirmatory testing is essential. False-negative rates have not been rigorously quantified. Our study estimates the false-negative rate of immunoassay screening in a pediatric population.

METHODS:

Drug screening in the St. Louis Children's laboratory employs a broad spectrum direct to LC-MS/MS approach. We selected 125 urine specimens over five months (4% of 3000 screens), that were weakly positive for amphetamines, benzoylecgonine, THC, opiates, fentanyl, benzodiazepines, and methadone using LC-MS/MS. These specimens were reanalyzed by immunoassay on a Roche Cobas platform (forward approach). Second, we collected 145 negative urine specimens from five pediatric settings using immunoassay platforms including Viva-ProE (Siemens), Vitros (Ortho), Atellica (Siemens) and Cobas (Roche). These specimens were subjected to our local LC-MS/MS analysis (reverse approach).

RESULTS:

Among the 125 LC-MS/MS positive samples, 112 (90%) contained at least one substance that was targeted but not detected by immunoassay. The most frequently missed substances were methamphetamine and benzoylecgonine. Among the 145 negative urine specimens from routine immunoassay, LC-MS/MS identified substances in 16 (11%) that were targeted and missed by immunoassay and identified substances in 34 (23%) that were not covered by immunoassay.

CONCLUSIONS:

Our study indicates that 4-11% of pediatric urine specimens contain substances targeted and missed by conventional immunoassays. Another quarter may contain substances not covered by immunoassay. These false negatives can lead to the discharge of a child into an unsafe environment. Direct to LC-MS/MS screening acts to minimize false-negative immunoassay drug screens.

660

项与屈大麻酚相关的新闻（医药）

2026-06-20

·Science Daily

Scientists found a cannabis compound that relieves pain without the high

Compounds responsible for the aroma of cannabis and many other plants may offer a surprising new way to relieve chronic pain. Researchers found that several cannabis-derived terpenes significantly reduced pain in mouse models of fibromyalgia and post-surgical pain, with one terpene, geraniol, showing especially strong effects. Unlike THC, these compounds are not associated with psychoactive effects, making them a potentially attractive alternative for pain treatment.Researchers at the University of Arizona Health Sciences have identified compounds from the Cannabis sativa plant that may offer a new way to treat fibromyalgia and post-surgical pain. The findings, published in Pharmacological Reports, add to growing evidence that certain cannabis-derived molecules could help relieve chronic pain without causing the psychoactive effects associated with THC. The study builds on earlier work from the lab of John Streicher, PhD, a member of the Comprehensive Center for Pain & Addiction, which found that terpenes could reduce pain in models of inflammation and chemotherapy-related nerve damage. "Our research is showing that terpenes are not a good option for reducing acute pain resulting from an injury, such as stubbing your toe or touching a hot stove; however, we are seeing significant reductions in pain when terpenes are used for chronic or pathological pain," said Streicher, who is a professor in the U of A College of Medicine -- Tucson's Department of Pharmacology. "This study was the first to investigate the impact of terpenes in preclinical models of fibromyalgia and post-operative pain and expand the scope of potential pain-relieving treatments using terpenes." Cannabis Terpenes Show Strong Pain Relief Terpenes are natural compounds responsible for the scent and flavor of many plants. In cannabis, they contribute to the plant's distinctive aroma and may also have medicinal properties. Unlike tetrahydrocannabinol, or THC, terpenes do not produce the unwanted psychoactive effects commonly associated with cannabis. That makes them an appealing area of research for scientists searching for new pain treatments. For this study, researchers examined four terpenes commonly found in Cannabis sativa: geraniol, linalool, beta-caryophyllene, and alpha-humulene. In mouse models of fibromyalgia and post-operative pain, all four compounds produced substantial pain-relieving effects. Geraniol delivered the strongest results, followed by linalool, beta-caryophyllene, and alpha-humulene. New Hope for Fibromyalgia Treatment Fibromyalgia remains one of the most challenging chronic pain conditions to treat. The disorder affects muscles and soft tissues throughout the body and is estimated to impact up to 5% of the global population, according to research published in Healthcare (Basel) in 2023. In the United States alone, about 4 million adults have fibromyalgia, according to the U.S. Department of Health and Human Services' Office on Women's Health. Women are affected more often than men. "With fibromyalgia, there isn't much understanding of what the pain state is, and there are not a lot of great options for treating it," Streicher said. "Our findings show that terpenes may be a viable treatment option for fibromyalgia pain, which could potentially have a large impact and make a difference for an under-treated population." Potential Alternative for Post-Surgical Pain The researchers also explored whether terpenes could help with pain following surgery. Post-surgical pain occupies a unique middle ground between acute and chronic pain. Although it is typically temporary, surgery triggers biological changes including inflammation and increased sensitivity within the body's pain pathways, which can intensify discomfort. "Opioids do a good job controlling post-surgical pain, but they can cause constipation that can increase the chances of post-surgical complications such as adhesions," Streicher said. "We are always looking for better options, and this study suggests that terpenes could be a novel therapeutic for post-operative pain." According to research published in the International Journal of Surgery in 2020, roughly 310 million major surgical procedures are performed worldwide each year, highlighting the need for safer and more effective pain-management options. Natural Compounds Continue to Surprise Scientists Todd Vanderah, PhD, director of the Comprehensive Center for Pain & Addiction at U of A Health Sciences and professor and head of the Department of Pharmacology at the U of A College of Medicine -- Tucson, said the findings underscore the value of exploring chemicals produced by nature. "The research that is being done by Dr. Streicher's lab on terpenes and their potential to help those who suffer from chronic pain demonstrates the importance of basic research. There are hundreds of unique chemicals that plants make, including the Cannabis plant, that are undiscovered," Vanderah said. "Nature is incredible at making unique chemical structures, and many of these chemicals are unknowns when it comes to their abilities to aid in human health, diseases and disorders. A great current example is medication semaglutide, sold under the brand name Ozempic, which has a chemical structure that was isolated not from a plant, but from an animal that is prevalent in the Southwest, the Gila monster. These discoveries from natural products through research such as Dr. Streicher's can result in very useful medications." How the Terpenes May Work The team also found that the compounds appeared to act through the same biological pathway identified in previous terpene studies. Specifically, the pain-relieving effects were linked to the adenosine A2a receptor -- a receptor that caffeine targets and blocks -- suggesting that terpenes may also have sedative properties. Researchers say that possibility warrants further investigation. The study's co-authors included Caleb Seekins, a former undergraduate biochemistry student in Streicher's lab who is now pursuing a medical degree at the College of Medicine -- Tucson; Alyssa Welborn, who earned a Bachelor of Science in Pharmaceutical Sciences in 2024; and Abigail Schwarz, who completed her doctorate in Streicher's lab in 2024. Funding for the research was provided by the National Institutes of Health under award no. R01AT011517.

2026-06-11

·动脉网

阿尔茨海默病激越症状市场在预测期（2026-2036年）将以14.9%的年均复合增长率实现巨大增长 DelveInsightAgitation in Alzheimer's Disease Market to Register Immense Growth at a CAGR of 14.9% During the Forecast Period (2026-2036)

The recent approval of Axsome Therapeutics' AUVELITY has transformed the agitation in Alzheimer's disease market. The emergence of investigational therapies, including IGC-AD1 (IGC Pharma), Masupirdine (SUVN-502) (Suven Life Sciences), EXV-801 ± Dextromethorphan (Exciva GmbH), COBENFY (KarXT; xanomeline–trospium chloride) (Bristol Myers Squibb/Karuna Therapeutics), and others, is also transforming the agitation in Alzheimer's disease treatment landscape through novel and diverse mechanisms of action. Axsome Therapeutics 公司的 AUVELITY 近期获批，已彻底改变阿尔茨海默病激越症状治疗市场。包括 IGC Pharma 的 IGC-AD1、Suven Life Sciences 的 Masupirdine（SUVN-502）、Exciva GmbH 的 EXV-801 ± 右美沙芬、Bristol Myers Squibb/Karuna Therapeutics 的 COBENFY（KarXT；昔诺美林–托吡氯铵）等在内的在研疗法的涌现，正通过新颖且多样的作用机制，重塑阿尔茨海默病激越症状的治疗格局。These advancing therapies are anticipated to broaden available treatment choices and support the ongoing evolution of the market.. 这些不断发展的疗法预计将扩大可用的治疗选择，并支持市场的持续演变。LAS VEGAS 拉斯维加斯, ，June 11, 2026 2026年6月11日/PRNewswire/ -- Recently published Agitation in Alzheimer's Disease Market Insights report includes a comprehensive understanding of current treatment practices, agitation in Alzheimer's disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].. /PRNewswire/ -- 最近发布的《阿尔茨海默病激越市场洞察》报告全面分析了当前的治疗实践、阿尔茨海默病激越在研新药、各疗法的市场份额，以及2022年至2036年的当前市场规模和预测市场规模，并按主要市场（美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本）进行了细分。Agitation in Alzheimer's Disease Market Summary 阿尔茨海默病激越症状市场概览The market size for agitation in Alzheimer's disease was found to be 阿尔茨海默病激越症状的市场规模被发现为USD 600 million 6亿美元in the 7MM in 2025. 在2025年的7MM中。The United States accounted for the largest agitation in Alzheimer's disease treatment market size, approximately 美国在阿尔茨海默病治疗市场规模中占据最大份额，约为83% 83%of the total market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. 占2025年七大主要市场（7MM）总市场规模的比例，并与包括欧盟四国（德国、法国、意大利和西班牙）、英国和日本在内的其他主要市场进行比较。The total number of diagnosed cases of agitation in alzheimer's in the 7MM is 在7MM中，阿尔茨海默病激越症状的确诊总病例数为~11 million 约1100万in 2025. 2025年。Leading agitation in Alzheimer's disease companies, such as 在阿尔茨海默病领域处于领先地位的公司，例如IGC Pharma, Suven Life Sciences, Exciva GmbH, Bristol Myers Squibb, Karuna Therapeutics, IGC Pharma，Suven Life Sciences，Exciva GmbH，百时美施贵宝，Karuna Therapeutics，and others, are developing new agitation in Alzheimer's disease treatment drugs that can be available in the agitation in Alzheimer's disease market in the coming years. 以及其他公司正在开发用于治疗阿尔茨海默病激越症状的新药，这些药物有望在未来几年内上市。The promising agitation in Alzheimer's disease therapies in clinical trials include 阿尔茨海默病治疗在临床试验中展现出的令人鼓舞的进展包括IGC-AD1, Masupirdine (SUVN-502), EXV-801 ± Dextromethorphan, COBENFY (KarXT; xanomeline–trospium chloride), IGC-AD1、Masupirdine（SUVN-502）、EXV-801 ± 右美沙芬、COBENFY（KarXT；卡诺美林–托哌氯铵）and others. 以及其他。Discover what is the future of the agitation in Alzheimer's disease treatment market @ 探索阿尔茨海默病治疗市场中激越症状的未来 @https://www.delveinsight.com/report-store/agitation-in-alzheimer-disease https://www.delveinsight.com/report-store/agitation-in-alzheimer-diseaseKey Factors Driving the Growth of the Agitation in Alzheimer's Disease Market 推动阿尔茨海默病激越症状市场增长的关键因素Rising Prevalence of Alzheimer's Disease: 阿尔茨海默病患病率持续上升：The increasing global burden of Alzheimer's disease is directly contributing to a larger patient pool experiencing agitation symptoms. In 2025, the total number of diagnosed cases of agitation in Alzheimer's disease in the 7MM was around 阿尔茨海默病的全球负担日益加重，直接导致出现激越症状的患者群体不断扩大。2025年，七大主要市场（7MM）中阿尔茨海默病伴发激越症状的确诊总病例数约为11 million 1100万. Among the 7MM countries, the US accounted for the highest number of diagnosed prevalent cases of Alzheimer's disease, contributing around 在七大主要市场国家中，美国确诊的阿尔茨海默病现患病例数最多，约占49% 49%, while the UK reported the lowest number of cases in 2025. ，而英国在2025年报告的病例数最少。Increasing Awareness and Early Diagnosis: 提高意识与早期诊断：Growing awareness among caregivers, physicians, and healthcare organizations is improving recognition of neuropsychiatric symptoms in Alzheimer's disease. 护理人员、医生和医疗保健机构对阿尔茨海默病神经精神症状的认识不断提高，从而改善了对这些症状的识别。Entry of Axsome Therapeutics' AUVELITY: Axsome Therapeutics公司AUVELITY的上市：In April 2026, Axsome Therapeutics secured FDA approval for AUVELITY to treat agitation associated with Alzheimer's-related dementia, making it the first oral non-antipsychotic therapy approved for this indication. The approval was backed by the Phase 3 ADVANCE-1 and ACCORD-2 trials. Previously approved in 2022 for MDD, the label expansion significantly enhances AUVELITY's therapeutic and commercial potential.. 2026年4月，Axsome Therapeutics获得美国食品药品监督管理局（FDA）批准，将AUVELITY用于治疗与阿尔茨海默病相关痴呆的激越症状，使其成为首个获批用于该适应症的口服非抗精神病药物疗法。此次批准基于ADVANCE-1和ACCORD-2两项III期临床试验的结果。AUVELITY此前于2022年获准用于治疗重度抑郁症（MDD），此次适应症扩展显著提升了其治疗价值和商业潜力。Emergence of Novel Therapies: 新疗法的涌现：The dynamics of the agitation in Alzheimer's disease market are expected to change in the coming years due to the launch of emerging therapies such as 阿尔茨海默病躁动治疗市场的动态预计将在未来几年因新兴疗法的上市而发生变化，例如IGC-AD1 IGC-AD1(IGC Pharma), (IGC Pharma),Masupirdine (SUVN-502) 马苏匹定（SUVN-502）(Suven Life Sciences), （苏文生命科学公司），EXV-801 ± Dextromethorphan EXV-801 ± 右美沙芬(Exciva GmbH), （Exciva 有限公司）COBENFY (KarXT; xanomeline–trospium chloride) COBENFY（KarXT；卡诺美林–托哌氯铵）(Bristol Myers Squibb/Karuna Therapeutics), and others. （百时美施贵宝/Karuna Therapeutics）及其他公司。Ramandeep Singh, a neurology expert at DelveInsight, said that with increasing clinical and commercial momentum, the space is poised for substantial evolution, and by 2036, COBENFY is expected to emerge as the leading revenue-generating therapy across the 7MM for this indication. DelveInsight的神经病学专家拉曼迪普·辛格（Ramandeep Singh）表示，随着临床和商业势头的不断增强，该领域有望迎来重大变革；到2036年，COBENFY预计将成为针对这一适应症在七大主要市场（7MM）中收入领先的治疗药物。Agitation in Alzheimer's Disease Market Analysis 阿尔茨海默病激越症状市场分析Despite the immense burden of disease, the treatment landscape for agitation in Alzheimer's disease has long relied more on clinical improvisation than targeted therapeutic precision. 尽管疾病负担沉重，阿尔茨海默病激越症状的治疗格局长期以来更依赖于临床上的临时应对，而非精准的靶向治疗。Real-world prescribing patterns show that atypical antipsychotics account for the majority of treatments (55.5% of prescriptions), followed by selective serotonin reuptake inhibitors (SSRIs) at 29.3% and benzodiazepines at 23.2%, all prescribed off-label for this indication. 真实世界中的处方模式显示，非典型抗精神病药物占治疗的大部分（55.5%的处方），其次是选择性5-羟色胺再摄取抑制剂（SSRIs），占29.3%，苯二氮䓬类药物占23.2%，所有这些药物均超说明书用于该适应症。Agents such as risperidone, quetiapine, olanzapine, and haloperidol have traditionally formed the backbone of management strategies, despite lacking formal approval for agitation in AD. Their widespread use has been accompanied by significant safety concerns, including sedation, falls, metabolic complications, cardiovascular risks, and notably, increased mortality among elderly patients.. 利培酮、喹硫平、奥氮平和氟哌啶醇等药物传统上构成了管理策略的核心，尽管它们尚未获得正式批准用于阿尔茨海默病（AD）相关的激越症状。这些药物的广泛使用伴随着显著的安全性担忧，包括镇静、跌倒、代谢并发症、心血管风险，以及尤为突出的老年患者死亡率增加。A major breakthrough came in 2023, when 2023年取得了一项重大突破，当时REXULTI 雷克斯蒂(brexpiprazole), jointly developed by （布瑞哌唑），由……联合开发Otsuka Pharmaceutical and Lundbeck 大冢制药和灵北制药, became the first FDA-approved therapy specifically indicated for agitation associated with Alzheimer's dementia. ，成为首个获美国食品药品监督管理局（FDA）批准、专门用于治疗阿尔茨海默病痴呆相关激越症状的疗法。Momentum in the field accelerated further in late April 2026, when 2026年4月下旬，该领域的势头进一步加速，当时Axsome Therapeutics Axsome Therapeuticssecured FDA approval for 获得美国食品药品监督管理局（FDA）批准AUVELITY 奥维利蒂(dextromethorphan hydrobromide/bupropion hydrochloride) for agitation associated with dementia due to Alzheimer's disease. The approval marked a significant milestone, making AUVELITY the first oral non-antipsychotic therapy approved for this condition. （氢溴酸右美沙芬/盐酸安非他酮）用于治疗阿尔茨海默病所致痴呆相关的激越症状。该批准标志着一个重要的里程碑，使AUVELITY成为首个获批用于此病症的口服非抗精神病疗法。The emergence of AUVELITY represents more than a single product approval; it signals an increasingly competitive and innovation-driven market. Several promising candidates are advancing through the pipeline, including AUVELITY 的问世不仅仅意味着单一产品的获批；它标志着一个竞争日益激烈、由创新驱动的市场正在形成。包括IGC-AD1 IGC-AD1(IGC Pharma), (IGC Pharma),Masupirdine (SUVN-502) 马苏吡啶（SUVN-502）(Suven Life Sciences), （苏文生命科学公司），EXV-801 ± Dextromethorphan EXV-801 ± 右美沙芬(Exciva GmbH), and （Exciva GmbH），以及COBENFY (KarXT; xanomeline–trospium chloride) COBENFY（KarXT；卡诺美林–氯化托斯比胺）from Bristol Myers Squibb/Karuna Therapeutics, among others. 来自百时美施贵宝/Karuna Therapeutics等公司。Agitation in Alzheimer's Disease Competitive Landscape 阿尔茨海默病激越症状的竞争格局Some of the agitation in Alzheimer's disease drugs under development include 正在研发中的阿尔茨海默病药物中，部分引发的争议包括IGC-AD1 IGC-AD1(IGC Pharma), (IGC Pharma),Masupirdine (SUVN-502) 马斯吡啶（SUVN-502）(Suven Life Sciences), （Suven生命科学公司），EXV-801 ± Dextromethorphan EXV-801 ± 右美沙芬(Exciva GmbH), （Exciva 有限公司），COBENFY (KarXT; xanomeline–trospium chloride) COBENFY（KarXT；卡诺美林–氯化托哌酮）(Bristol Myers Squibb/Karuna Therapeutics), and others. （百时美施贵宝/卡鲁纳治疗公司）等。IGC Pharma's IGC-AD1 (melatonin/tetrahydrocannabinol) IGC Pharma 公司的 IGC-AD1（褪黑素/四氢大麻酚）is an investigational combination therapy for agitation linked to Alzheimer's disease. By integrating THC with melatonin, the therapy is designed to influence neuroinflammatory pathways, neuronal communication, and circadian rhythm regulation, to alleviate agitation and improve behavioral outcomes in patients who currently have limited therapeutic options.. 是一种针对阿尔茨海默病相关激越症状的研究性联合疗法。该疗法通过将四氢大麻酚（THC）与褪黑素相结合，旨在影响神经炎症通路、神经元通讯以及昼夜节律调节，从而减轻激越症状并改善目前治疗选择有限的患者的行为结局。Suven Life Sciences' Masupirdine Suven生命科学公司的Masupirdine, a selective 5-HT6 receptor antagonist, represents a non-dopaminergic strategy aimed at stabilizing symptoms through serotonin pathway modulation. Its global Phase III study had reached nearly 50% enrollment by November 2025, and topline findings are expected in Q1/Q2 2027. ，一种选择性5-HT6受体拮抗剂，代表了一种通过调节血清素通路来稳定症状的非多巴胺能策略。截至2025年11月，其全球III期研究的入组率已接近50%，预计将于2027年第一季度或第二季度公布主要结果。Meanwhile, 与此同时，Bristol Myers Squibb/Karuna Therapeutics' COBENFY 百时美施贵宝/卡拉纳治疗公司的COBENFY, which has already generated significant interest in schizophrenia treatment, is being explored for agitation in Alzheimer's disease via muscarinic receptor modulation, offering a cholinergic mechanism that may also support cognitive function. 该药物已在精神分裂症治疗领域引起广泛关注，目前正通过调节毒蕈碱受体探索其在阿尔茨海默病激越症状中的应用，其胆碱能机制也可能有助于支持认知功能。Exciva GmbH's EXV-802 Exciva GmbH 的 EXV-802, an advanced Phase II/III neuroactive therapy candidate under investigation both as a standalone treatment and in combination with EXV-801 to address multiple CNS signaling pathways associated with agitation. This reflects an industry-wide move toward multi-target and combination-based therapeutic strategies intended to enhance efficacy while maintaining functional tolerability in complex neurobehavioral conditions. ，一种先进的处于II/III期临床试验阶段的神经活性疗法候选药物，正在作为单一疗法以及与EXV-801联合用药进行研究，旨在针对与激越相关的多种中枢神经系统信号通路。这反映了整个行业向多靶点和基于联合治疗的策略转变，以期在复杂的神经行为障碍中提高疗效，同时保持功能性的耐受性。In November 2024, EXV-802 also received Fast Track Designation from the US FDA for the treatment of agitation associated with Alzheimer's disease.. 2024年11月，EXV-802还获得了美国食品药品监督管理局（FDA）授予的“快速通道资格”，用于治疗与阿尔茨海默病相关的激越症状。The anticipated launch of these emerging therapies are poised to transform the agitation in Alzheimer's disease market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the agitation in Alzheimer's disease market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.. 这些新兴疗法的预期上市将在未来几年内彻底改变阿尔茨海默病相关激越症状的治疗市场格局。随着这些前沿疗法不断成熟并获得监管批准，它们有望重塑阿尔茨海默病相关激越症状的市场格局，提供新的护理标准，并为医疗创新和经济增长带来新机遇。Discover more about which pipeline drugs could transform agitation in Alzheimer's disease treatment @ 了解更多关于哪些在研药物可能改变阿尔茨海默病激越症状的治疗 @Agitation in Alzheimer's Disease Drugs 阿尔茨海默病药物中的激越症状Recent Developments in the Agitation in Alzheimer's Disease Market 阿尔茨海默病躁动症治疗市场的最新进展In 在April 2026, Axsome Therapeutics, Inc. 2026年4月，Axsome Therapeutics公司announced that the FDA had approved AUVELITY for managing agitation linked to dementia caused by Alzheimer's disease. AUVELITY becomes the first treatment of its kind for Alzheimer's-related agitation, acting through modulation of the NMDA and sigma-1 receptors. 宣布美国食品药品监督管理局（FDA）已批准AUVELITY用于治疗阿尔茨海默病所致痴呆相关的激越症状。AUVELITY成为首款针对阿尔茨海默病相关激越症状的同类治疗药物，其作用机制为调节NMDA受体和sigma-1受体。In 在February 2026, IGC Pharma 2026年2月，IGC Pharmareported that approximately 70% of the planned enrollment in its ongoing randomized, double-blind, placebo-controlled Phase II CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease had been completed. 报告称，其正在进行的随机、双盲、安慰剂对照的II期CALMA试验（评估IGC-AD1用于阿尔茨海默病相关激越症状）的计划入组人数已完成约70%。In 在November 2025, Suven Life Sciences 2025年11月，Suven Life Sciencesreported that its global Phase III clinical trial of masupirdine (SUVN-502) achieved 50% patient enrollment for agitation in Alzheimer's disease, with the multicenter, randomized, double-blind, placebo-controlled study ongoing across North America and Europe. 报告称，其针对马斯匹尔定（SUVN-502）的全球III期临床试验在阿尔茨海默病激越症状患者入组方面已达到50%，这项多中心、随机、双盲、安慰剂对照研究正在北美和欧洲持续进行。What is Agitation in Alzheimer's Disease? 什么是阿尔茨海默病中的激越症状？Agitation in Alzheimer's disease refers to a cluster of behavioral and emotional symptoms characterized by excessive restlessness, irritability, aggression, emotional distress, or inappropriate verbal and physical behaviors that occur in individuals with Alzheimer's-related dementia. It is one of the most common neuropsychiatric manifestations of the disease and can include pacing, shouting, resistance to care, wandering, verbal outbursts, or physical aggression. 阿尔茨海默病中的激越症状是指在与阿尔茨海默病相关的痴呆患者中出现的一组行为和情绪症状，其特征为过度坐立不安、易怒、攻击性、情绪痛苦或不适当的言语和身体行为。它是该疾病最常见的神经精神表现之一，可包括踱步、喊叫、抗拒护理、游荡、言语爆发或身体攻击。Agitation often arises from a combination of cognitive decline, impaired communication, environmental stressors, unmet physical or emotional needs, and underlying neurobiological changes associated with disease progression. These symptoms can significantly impair quality of life, increase caregiver burden, accelerate institutionalization, and complicate disease management, making agitation a major clinical challenge in Alzheimer's disease care.. 激越症状往往由认知功能衰退、沟通障碍、环境压力源、未得到满足的生理或情感需求，以及与疾病进展相关的潜在神经生物学变化共同引发。这些症状会显著降低患者的生活质量，加重照护者负担，加速机构化照护进程，并使疾病管理复杂化，因此激越成为阿尔茨海默病照护中的一大临床挑战。Agitation in Alzheimer's Disease Epidemiology Segmentation 阿尔茨海默病躁动症状的流行病学细分The agitation in Alzheimer's disease epidemiology section provides insights into the historical and current agitation in Alzheimer's disease patient pool and forecasted trends for the leading markets. According to DelveInsight's estimates, in the United States, diagnosed cases of agitation in Alzheimer's disease are predominantly made up of females, accounting for . 阿尔茨海默病流行病学章节中的激越症状部分提供了对阿尔茨海默病患者群体中历史及当前激越症状状况的洞察，并预测了主要市场的发展趋势。根据 DelveInsight 的估算，在美国，确诊的阿尔茨海默病激越症状病例主要以女性为主，占比为。~3 million 约300万cases in 2025. 2025年的案例。The agitation in Alzheimer's disease treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into: 《阿尔茨海默病治疗市场躁动报告》提供了2022–2036年研究期间主要市场的流行病学分析，细分如下：Total Diagnosed Prevalent Cases of Alzheimer's Disease. 阿尔茨海默病确诊患病总病例数。Total Diagnosed Prevalent Cases of Agitation in Alzheimer's disease. 阿尔茨海默病中激越症状的确诊总患病人数Gender-specific Diagnosed Prevalent Cases of Agitation in Alzheimer's disease. 阿尔茨海默病中激越症状的性别特异性诊断患病病例数Age-specific Diagnosed Prevalent Cases of Agitation in Alzheimer's disease. 阿尔茨海默病中躁动症状的年龄别确诊患病病例数Total Treated Cases of Agitation in Alzheimer's Disease 阿尔茨海默病激越症状的总治疗病例数Agitation in Alzheimer's Disease Market Report Metrics 阿尔茨海默病激越症状市场报告指标Details 详情Study Period 研究期间2022–2036 2022–2036Coverage 覆盖范围7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 700万[美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本]。Agitation in Alzheimer's Disease Market CAGR 阿尔茨海默病躁动症市场复合年增长率14.9% 14.9%Agitation in Alzheimer's Disease Market Size in 2025 2025年阿尔茨海默病激越症状治疗市场规模USD 600 Million 6亿美元Key Agitation in Alzheimer's Disease Companies 阿尔茨海默病领域主要企业的激越症状研究IGC Pharma, Suven Life Sciences, Exciva GmbH, Bristol Myers Squibb, Karuna Therapeutics, Otsuka Pharmaceutical, Lundbeck, Axsome Therapeutics, and others IGC Pharma、Suven Life Sciences、Exciva GmbH、百时美施贵宝、Karuna Therapeutics、大冢制药、灵北制药、Axsome Therapeutics 等Key Agitation in Alzheimer's Disease Therapies 阿尔茨海默病治疗中的关键激越症状IGC-AD1, Masupirdine (SUVN-502), EXV-801 ± Dextromethorphan, COBENFY (KarXT; xanomeline–trospium chloride), REXULTI, AUVELITY, and others IGC-AD1、Masupirdine（SUVN-502）、EXV-801 ± 右美沙芬、COBENFY（KarXT；卡诺美林–氯化托斯品）、REXULTI、AUVELITY 等Scope of the 范围Agitation in Alzheimer's Disease 阿尔茨海默病中的激越症状Market Report 市场报告Agitation in Alzheimer's Disease Patient Population Forecast 阿尔茨海默病患者人群激越症状预测Agitation in Alzheimer's Disease Therapeutics Market Size 阿尔茨海默病躁动治疗市场规模Agitation in Alzheimer's Disease Pipeline Analysis 阿尔茨海默病激越症状在研药物管线分析Agitation in Alzheimer's Disease Market Size and Trends 阿尔茨海默病激越症状市场规模与趋势Agitation in Alzheimer's Disease Market Opportunity 阿尔茨海默病激越症状市场机遇Agitation in Alzheimer's Disease Market Unmet Needs 阿尔茨海默病激越症状市场的未满足需求KOL's Views on Agitation in Alzheimer's Disease 关键意见领袖对阿尔茨海默病激越症状的观点Agitation in Alzheimer's Disease Market Access and Reimbursement 阿尔茨海默病激越症状的市场准入与报销Download the report to understand the top emerging therapies in agitation in Alzheimer's disease @ 下载报告，了解阿尔茨海默病激越症状领域最前沿的新兴疗法Agitation in Alzheimer's Disease Market Analysis 阿尔茨海默病激越症状市场分析Table of Contents 目录1 1Agitation in Alzheimer's Disease Market Key Insights 阿尔茨海默病躁动市场关键洞察2 2Agitation in Alzheimer's Disease Market Report Introduction 阿尔茨海默病激越症状市场报告引言3 3Agitation in Alzheimer's Disease Market Overview at a Glance 阿尔茨海默病激越症状市场概览一览3.1 3.1Market Share (%) Distribution of Agitation in Alzheimer's Disease by Therapies in the 7MM in 2025 2025年七大主要市场（7MM）中按治疗方式划分的阿尔茨海默病激越症状市场份额（%）分布3.2 3.2Market Share (%) Distribution of Agitation in Alzheimer's Disease by Therapies in the 7MM in 2036 2036年七大主要市场阿尔茨海默病激越症状治疗的市场份额（%）分布4 4Executive Summary 执行摘要5 5Key Events 关键事件5.1 5.1Key Transactions and Collaborations 关键交易与合作5.2 5.2News Flow 新闻动态6 6Disease Background and Overview 疾病背景与概述6.1 6.1Introduction 简介6.2 6.2Type and Severity 类型和严重程度6.3 6.3Etiology 病因学6.4 6.4Risk Factors 风险因素6.5 6.5Signs and Symptoms 体征与症状6.6 6.6Common Manifestations of Agitation 激越的常见表现6.7 6.7Pathophysiology 病理生理学6.8 6.8Diagnosis 诊断6.9 6.9Treatment and Management 治疗与管理6.10 6.10Diagnosis and Treatment Guidelines 诊断与治疗指南7 7Epidemiology and Market Forecast Methodology 流行病学与市场预测方法论8 8Epidemiology and Patient Population 流行病学与患者人群8.1 8.1Key Findings 主要发现8.2 8.2Assumptions and Rationale: The 7MM 假设与理由：7MM8.2.1 8.2.1Diagnosed Prevalent Cases of Alzheimer's Disease 阿尔茨海默病确诊现患病例8.2.2 8.2.2Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease 阿尔茨海默病中激越症状的确诊现患病例8.2.3 8.2.3Gender-specific Diagnosed Prevalent Cases 按性别划分的确诊患病病例8.2.4 8.2.4Age-specific Diagnosed Prevalent Cases 按年龄分组的确诊患病病例数8.2.5 8.2.5Total Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in the 7MM 7MM中阿尔茨海默病激越症状的确诊患病总病例数8.3 8.3The US 美国8.3.1 8.3.1Total Diagnosed Prevalent Cases of Alzheimer's Disease in the US 美国阿尔茨海默病确诊患病总人数8.3.2 8.3.2Total Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in the US 美国阿尔茨海默病伴激越症状的确诊现患病例总数8.3.3 8.3.3Gender-specific Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in the US 美国阿尔茨海默病患者中激越症状的性别特异性诊断患病病例数8.3.4 8.3.4Age-specific Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in the US 美国阿尔茨海默病患者中按年龄分层的激越症状确诊患病病例数8.3.5 8.3.5Total Treated Cases of Agitation in Alzheimer's Disease in the US 美国阿尔茨海默病激越症状的总治疗病例数8.4 8.4EU4 and the UK 欧盟与英国8.5 8.5Japan 日本9 9Patient Journey 患者旅程10 10Marketed Agitation in Alzheimer's Disease Therapies 阿尔茨海默病治疗中的激越症状管理10.1 10.1Brexpiprazole (REXULTI): Otsuka Pharmaceutical/Lundbeck 布雷哌唑（REXULTI）：大冢制药/灵北10.1.1 10.1.1Product Description 产品描述10.1.2 10.1.2Regulatory Milestones 监管里程碑10.1.3 10.1.3Other Developmental Activities 其他发展活动10.1.4 10.1.4Summary of Pivotal Trials 关键性试验总结10.1.5 10.1.5Analyst Views 分析师观点10.2 10.2AUVELITY: Axsome Therapeutics AUVELITY：Axsome TherapeuticsThe list will be continued in the final report.. 该列表将在最终报告中继续列出。11 十一Emerging Agitation in Alzheimer's Disease Drugs 阿尔茨海默病药物中新兴的激越症状11.1 11.1Competitive Landscape: Emerging Drugs 竞争格局：新兴药物11.2 11.2IGC-AD1: IGC Pharma IGC-AD1：IGC Pharma11.2.1 11.2.1Drug Description 药物说明11.2.2 11.2.2Other Developmental Activities 其他发展活动11.2.3 11.2.3Clinical Development Activity 临床开发活动11.2.4 11.2.4Safety and Efficacy 安全性和有效性11.2.5 11.2.5Analyst Views 分析师观点11.3 11.3Masupirdine (SUVN-502): Suven Life Sciences 马苏吡啶（SUVN-502）：Suven生命科学公司11.4 11.4EXV-801 ± Dextromethorphan: Exciva GmbH EXV-801 ± 右美沙芬：Exciva GmbH11.5 11.5COBENFY (KarXT; xanomeline–trospium chloride): Bristol Myers Squibb/Karuna Therapeutics COBENFY（KarXT；卡诺美林–氯化托斯匹胺）：百时美施贵宝/Karuna TherapeuticsThe list will be continued in the final report.. 该列表将在最终报告中继续列出。12 12Agitation in Alzheimer's Disease Market – The 7MM Market Analysis 阿尔茨海默病激越症状市场——七大主要国家市场分析12.1 12.1Key Findings 主要发现12.2 12.2Key Agitation in Alzheimer's Disease Market Forecast Assumptions 阿尔茨海默病市场中关键激越症状的预测假设12.3 12.3Market Outlook 市场展望12.4 12.4Conjoint Analysis 联合分析12.5 12.5Market Size of Agitation in Alzheimer's Disease in the 7MM 阿尔茨海默病激越症状在七大主要市场的市场规模12.6 12.6Market Size of Agitation in Alzheimer's Disease by Therapies in the 7MM 七大主要市场阿尔茨海默病激越症状治疗市场规模12.7 12.7The United States Agitation in Alzheimer's Disease Market Size 美国阿尔茨海默病激越症状治疗市场规模12.7.1 12.7.1Total Market Size of Agitation in Alzheimer's Disease in the US 美国阿尔茨海默病激越症状的总体市场规模12.7.2 12.7.2Market Size of Agitation in Alzheimer's Disease by Therapies in the US 美国按疗法划分的阿尔茨海默病激越症状市场规模12.8 12.8EU4 and the UK Agitation in Alzheimer's Disease Market Size 欧盟四国及英国阿尔茨海默病市场中的激动症状市场规模12.9 12.9Japan Agitation in Alzheimer's Disease Market Size 日本阿尔茨海默病市场的规模13 13Key Opinion Leaders' Views 关键意见领袖的观点14 14Unmet Needs 未满足的需求15 十五SWOT Analysis SWOT分析16 16Market access and reimbursement 市场准入与报销16.1 16.1The United States 美国16.2 16.2EU4 and the UK 欧盟四国与英国16.3 16.3Japan 日本16.4 16.4Market Access and Reimbursement of Agitation in Alzheimer's Disease Therapies 阿尔茨海默病激越症状治疗药物的市场准入与报销17 17Bibliography 参考文献18 十八Agitation in Alzheimer's Disease Market Report Methodology 阿尔茨海默病激越症状市场报告方法论Related Reports 相关报告Alzheimer's Disease 阿尔茨海默病Market 市场Alzheimer's Disease 阿尔茨海默病Market Insights, Epidemiology, and Market Forecast 市场洞察、流行病学及市场预测– –2036 2036report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer's disease companies, including 报告提供了对疾病的深入理解，包括历史和预测的流行病学数据，以及市场趋势、市场驱动因素、市场障碍和关键的阿尔茨海默病公司，包括Novo Nordisk, Eli Lilly, Suven Life Sciences, Bristol Myers Squibb, IGC Pharma, T3D Therapeutics, Lexeo Therapeutics, Axsome Therapeutics, Araclon Biotech S.L., Eisai, TauRx Therapeutics, GemVax & KAEL, AC Immune SA, Johnson & Johnson, Longeveron, Vaccinex, Sinaptica Therapeutics 诺和诺德、礼来、Suven Life Sciences、百时美施贵宝、IGC Pharma、T3D Therapeutics、Lexeo Therapeutics、Axsome Therapeutics、Araclon Biotech S.L.、卫材、TauRx Therapeutics、GemVax & KAEL、AC Immune SA、强生、Longeveron、Vaccinex、Sinaptica Therapeutics, ，and others. 以及其他。Alzheimer's Disease Clinical Trial Analysis 阿尔茨海默病临床试验分析Alzheimer's Disease Pipeline Insight – 2026 阿尔茨海默病研发管线洞察 – 2026report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Alzheimer's Disease companies, including 报告提供了关于管线格局、管线药物概况（包括临床和非临床阶段产品）以及关键阿尔茨海默病公司的全面洞察，包括Biogen, AZTherapies, Cerecin, Neurotrope, Synaptogenix, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Denali Therapeutics Inc., Alector Inc., Lexeo Therapeutics, TrueBinding, Inc., Vaccinex Inc., Annovis Bio Inc., Eisai Inc., Hoffmann-La Roche, Ionis Pharmaceuticals, Inc.,. 渤健、AZTherapies、Cerecin、Neurotrope、Synaptogenix、INmune Bio、木薯科学、EIP Pharma、Neuraly、AB Science、Cortexyme、Anavex Life Sciences、Athira Pharma、Time Therapeutics、Denali Therapeutics Inc.、Alector Inc.、Lexeo Therapeutics、TrueBinding, Inc.、Vaccinex Inc.、Annovis Bio Inc.、卫材株式会社、罗氏、Ionis Pharmaceuticals, Inc.。Otsuka Pharmaceutical Co., Ltd., 大冢制药有限公司Cognition Therapeutics, Merck Sharp & Dohme LLC, ImmunoBrain Checkpoint, AbbVie, AriBio Co., Ltd., Cognition Therapeutics，默沙东有限责任公司，ImmunoBrain Checkpoint，艾伯维，AriBio有限公司，Oryzon Genomics S.A., Eli Lilly and Company, Neurokine Therapeutics, Excelsior, Seelos Therapeutics, Inc., Janssen Research & Development, LLC, Shanghai Hengrui Pharmaceutical Co., Ltd., reMYND, Alzinova AB, VTBIO Co. LTD, BioVie Inc., Prothena Corporation plc, Coya Therapeutics, Inc., Oryzon Genomics S.A.、礼来公司（Eli Lilly and Company）、Neurokine Therapeutics、Excelsior、Seelos Therapeutics, Inc.、Janssen Research & Development, LLC、上海恒瑞医药有限公司、reMYND、Alzinova AB、VTBIO Co. LTD、BioVie Inc.、Prothena Corporation plc、Coya Therapeutics, Inc.，and others. 以及其他。Psychosis in Parkinson's and Alzheimer's Disease Market 帕金森病和阿尔茨海默病精神病市场Psychosis in Parkinson's and Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2036 帕金森病和阿尔茨海默病相关精神病市场洞察、流行病学及市场预测（至2036年）report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psychosis in Parkinson's and Alzheimer's disease companies, including 本报告深入解析疾病本身、历史及预测流行病学，以及市场趋势、市场驱动因素、市场壁垒，并重点分析帕金森病和阿尔茨海默病领域的主要企业，包括Sunovion Pharmaceuticals, Karuna Therapeutics, Vanda Pharmaceuticals, Suven Life Sciences, Enterin, Intra-Cellular Therapies, Merck Sharp & Dohme, 苏诺维昂制药公司、Karuna治疗公司、万达制药公司、Suven生命科学公司、Enterin公司、Intra-Cellular治疗公司、默沙东公司，and others. 以及其他。Parkinson's Disease Market 帕金森病市场Parkinson's Disease Market Insights, Epidemiology, and Market Forecast – 2036 帕金森病市场洞察、流行病学及市场预测——2036年report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease companies, including 报告深入解析了该疾病、历史及预测流行病学，以及市场趋势、市场驱动因素、市场壁垒和帕金森病领域的主要企业，包括UCB Biopharma SRL, Novartis, Annovis Bio, Supernus Pharmaceuticals, Inc., Britannia Pharmaceutical, Pharma Two B, Mitsubishi Tanabe Pharma (NeuroDerm), AbbVie, Cerevel Therapeutics, LLC, 优时比生物制药有限公司、诺华、Annovis Bio、Supernus Pharmaceuticals, Inc.、Britannia Pharmaceutical、Pharma Two B、三菱田边制药（NeuroDerm）、艾伯维、Cerevel Therapeutics, LLC，and others. 以及其他。About 关于DelveInsight DelveInsightDelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platformPharmDelve. DelveInsight 是一家领先的商业咨询和市场研究公司，专注于生命科学领域。它通过提供全面的端到端解决方案，帮助制药公司提升业绩。通过我们基于订阅的平台 PharmDelve，您可以轻松获取所有医疗保健和制药市场研究报告。. 。Contact Us 联系我们Shruti Thakur 什鲁蒂·塔库尔[emailprotected] [emailprotected]+14699457679 +14699457679www.delveinsight.com www.delveinsight.comSOURCE DelveInsight Business Research, LLP 来源：DelveInsight Business Research, LLP21 二十一% %more press release views with 更多新闻稿浏览量，使用Request a Demo 申请演示

2026-06-11

·PRNewswire

Agitation in Alzheimer's Disease Market to Register Immense Growth at a CAGR of 14.9% During the Forecast Period (2026-2036) | DelveInsight

The recent approval of Axsome Therapeutics' AUVELITY has transformed the agitation in Alzheimer's disease market. The emergence of investigational therapies, including IGC-AD1 (IGC Pharma), Masupirdine (SUVN-502) (Suven Life Sciences), EXV-801 ± Dextromethorphan (Exciva GmbH), COBENFY (KarXT; xanomeline–trospium chloride) (Bristol Myers Squibb/Karuna Therapeutics), and others, is also transforming the agitation in Alzheimer's disease treatment landscape through novel and diverse mechanisms of action. These advancing therapies are anticipated to broaden available treatment choices and support the ongoing evolution of the market. LAS VEGAS, June 11, 2026 /PRNewswire/ -- Recently published Agitation in Alzheimer's Disease Market Insights report includes a comprehensive understanding of current treatment practices, agitation in Alzheimer's disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Agitation in Alzheimer's Disease Market Summary The market size for agitation in Alzheimer's disease was found to be USD 600 million in the 7MM in 2025. The United States accounted for the largest agitation in Alzheimer's disease treatment market size, approximately 83% of the total market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The total number of diagnosed cases of agitation in alzheimer's in the 7MM is ~11 million in 2025. Leading agitation in Alzheimer's disease companies, such as IGC Pharma, Suven Life Sciences, Exciva GmbH, Bristol Myers Squibb, Karuna Therapeutics, and others, are developing new agitation in Alzheimer's disease treatment drugs that can be available in the agitation in Alzheimer's disease market in the coming years. The promising agitation in Alzheimer's disease therapies in clinical trials include IGC-AD1, Masupirdine (SUVN-502), EXV-801 ± Dextromethorphan, COBENFY (KarXT; xanomeline–trospium chloride), and others. Discover what is the future of the agitation in Alzheimer's disease treatment market @ Key Factors Driving the Growth of the Agitation in Alzheimer's Disease Market Rising Prevalence of Alzheimer's Disease: The increasing global burden of Alzheimer's disease is directly contributing to a larger patient pool experiencing agitation symptoms. In 2025, the total number of diagnosed cases of agitation in Alzheimer's disease in the 7MM was around 11 million. Among the 7MM countries, the US accounted for the highest number of diagnosed prevalent cases of Alzheimer's disease, contributing around 49%, while the UK reported the lowest number of cases in 2025. Increasing Awareness and Early Diagnosis: Growing awareness among caregivers, physicians, and healthcare organizations is improving recognition of neuropsychiatric symptoms in Alzheimer's disease. Entry of Axsome Therapeutics' AUVELITY: In April 2026, Axsome Therapeutics secured FDA approval for AUVELITY to treat agitation associated with Alzheimer's-related dementia, making it the first oral non-antipsychotic therapy approved for this indication. The approval was backed by the Phase 3 ADVANCE-1 and ACCORD-2 trials. Previously approved in 2022 for MDD, the label expansion significantly enhances AUVELITY's therapeutic and commercial potential. Emergence of Novel Therapies: The dynamics of the agitation in Alzheimer's disease market are expected to change in the coming years due to the launch of emerging therapies such as IGC-AD1 (IGC Pharma), Masupirdine (SUVN-502) (Suven Life Sciences), EXV-801 ± Dextromethorphan (Exciva GmbH), COBENFY (KarXT; xanomeline–trospium chloride) (Bristol Myers Squibb/Karuna Therapeutics), and others. Ramandeep Singh, a neurology expert at DelveInsight, said that with increasing clinical and commercial momentum, the space is poised for substantial evolution, and by 2036, COBENFY is expected to emerge as the leading revenue-generating therapy across the 7MM for this indication. Agitation in Alzheimer's Disease Market Analysis Despite the immense burden of disease, the treatment landscape for agitation in Alzheimer's disease has long relied more on clinical improvisation than targeted therapeutic precision. Real-world prescribing patterns show that atypical antipsychotics account for the majority of treatments (55.5% of prescriptions), followed by selective serotonin reuptake inhibitors (SSRIs) at 29.3% and benzodiazepines at 23.2%, all prescribed off-label for this indication. Agents such as risperidone, quetiapine, olanzapine, and haloperidol have traditionally formed the backbone of management strategies, despite lacking formal approval for agitation in AD. Their widespread use has been accompanied by significant safety concerns, including sedation, falls, metabolic complications, cardiovascular risks, and notably, increased mortality among elderly patients. A major breakthrough came in 2023, when REXULTI (brexpiprazole), jointly developed by Otsuka Pharmaceutical and Lundbeck, became the first FDA-approved therapy specifically indicated for agitation associated with Alzheimer's dementia. Momentum in the field accelerated further in late April 2026, when Axsome Therapeutics secured FDA approval for AUVELITY (dextromethorphan hydrobromide/bupropion hydrochloride) for agitation associated with dementia due to Alzheimer's disease. The approval marked a significant milestone, making AUVELITY the first oral non-antipsychotic therapy approved for this condition. The emergence of AUVELITY represents more than a single product approval; it signals an increasingly competitive and innovation-driven market. Several promising candidates are advancing through the pipeline, including IGC-AD1 (IGC Pharma), Masupirdine (SUVN-502) (Suven Life Sciences), EXV-801 ± Dextromethorphan (Exciva GmbH), and COBENFY (KarXT; xanomeline–trospium chloride) from Bristol Myers Squibb/Karuna Therapeutics, among others. Agitation in Alzheimer's Disease Competitive Landscape Some of the agitation in Alzheimer's disease drugs under development include IGC-AD1 (IGC Pharma), Masupirdine (SUVN-502) (Suven Life Sciences), EXV-801 ± Dextromethorphan (Exciva GmbH), COBENFY (KarXT; xanomeline–trospium chloride) (Bristol Myers Squibb/Karuna Therapeutics), and others. IGC Pharma's IGC-AD1 (melatonin/tetrahydrocannabinol) is an investigational combination therapy for agitation linked to Alzheimer's disease. By integrating THC with melatonin, the therapy is designed to influence neuroinflammatory pathways, neuronal communication, and circadian rhythm regulation, to alleviate agitation and improve behavioral outcomes in patients who currently have limited therapeutic options. Suven Life Sciences' Masupirdine, a selective 5-HT6 receptor antagonist, represents a non-dopaminergic strategy aimed at stabilizing symptoms through serotonin pathway modulation. Its global Phase III study had reached nearly 50% enrollment by November 2025, and topline findings are expected in Q1/Q2 2027. Meanwhile, Bristol Myers Squibb/Karuna Therapeutics' COBENFY, which has already generated significant interest in schizophrenia treatment, is being explored for agitation in Alzheimer's disease via muscarinic receptor modulation, offering a cholinergic mechanism that may also support cognitive function. Exciva GmbH's EXV-802, an advanced Phase II/III neuroactive therapy candidate under investigation both as a standalone treatment and in combination with EXV-801 to address multiple CNS signaling pathways associated with agitation. This reflects an industry-wide move toward multi-target and combination-based therapeutic strategies intended to enhance efficacy while maintaining functional tolerability in complex neurobehavioral conditions. In November 2024, EXV-802 also received Fast Track Designation from the US FDA for the treatment of agitation associated with Alzheimer's disease. The anticipated launch of these emerging therapies are poised to transform the agitation in Alzheimer's disease market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the agitation in Alzheimer's disease market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. Discover more about which pipeline drugs could transform agitation in Alzheimer's disease treatment @ Agitation in Alzheimer's Disease Drugs Recent Developments in the Agitation in Alzheimer's Disease Market In April 2026, Axsome Therapeutics, Inc. announced that the FDA had approved AUVELITY for managing agitation linked to dementia caused by Alzheimer's disease. AUVELITY becomes the first treatment of its kind for Alzheimer's-related agitation, acting through modulation of the NMDA and sigma-1 receptors. In February 2026, IGC Pharma reported that approximately 70% of the planned enrollment in its ongoing randomized, double-blind, placebo-controlled Phase II CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease had been completed. In November 2025, Suven Life Sciences reported that its global Phase III clinical trial of masupirdine (SUVN-502) achieved 50% patient enrollment for agitation in Alzheimer's disease, with the multicenter, randomized, double-blind, placebo-controlled study ongoing across North America and Europe. What is Agitation in Alzheimer's Disease? Agitation in Alzheimer's disease refers to a cluster of behavioral and emotional symptoms characterized by excessive restlessness, irritability, aggression, emotional distress, or inappropriate verbal and physical behaviors that occur in individuals with Alzheimer's-related dementia. It is one of the most common neuropsychiatric manifestations of the disease and can include pacing, shouting, resistance to care, wandering, verbal outbursts, or physical aggression. Agitation often arises from a combination of cognitive decline, impaired communication, environmental stressors, unmet physical or emotional needs, and underlying neurobiological changes associated with disease progression. These symptoms can significantly impair quality of life, increase caregiver burden, accelerate institutionalization, and complicate disease management, making agitation a major clinical challenge in Alzheimer's disease care. Agitation in Alzheimer's Disease Epidemiology Segmentation The agitation in Alzheimer's disease epidemiology section provides insights into the historical and current agitation in Alzheimer's disease patient pool and forecasted trends for the leading markets. According to DelveInsight's estimates, in the United States, diagnosed cases of agitation in Alzheimer's disease are predominantly made up of females, accounting for ~3 million cases in 2025. The agitation in Alzheimer's disease treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into: Total Diagnosed Prevalent Cases of Alzheimer's Disease. Total Diagnosed Prevalent Cases of Agitation in Alzheimer's disease. Gender-specific Diagnosed Prevalent Cases of Agitation in Alzheimer's disease. Age-specific Diagnosed Prevalent Cases of Agitation in Alzheimer's disease. Total Treated Cases of Agitation in Alzheimer's Disease Scope of the Agitation in Alzheimer's Disease Market Report Agitation in Alzheimer's Disease Patient Population Forecast Agitation in Alzheimer's Disease Therapeutics Market Size Agitation in Alzheimer's Disease Pipeline Analysis Agitation in Alzheimer's Disease Market Size and Trends Agitation in Alzheimer's Disease Market Opportunity Agitation in Alzheimer's Disease Market Unmet Needs KOL's Views on Agitation in Alzheimer's Disease Agitation in Alzheimer's Disease Market Access and Reimbursement Download the report to understand the top emerging therapies in agitation in Alzheimer's disease @ Agitation in Alzheimer's Disease Market Analysis Table of Contents Related Reports Alzheimer's Disease Market Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer's disease companies, including Novo Nordisk, Eli Lilly, Suven Life Sciences, Bristol Myers Squibb, IGC Pharma, T3D Therapeutics, Lexeo Therapeutics, Axsome Therapeutics, Araclon Biotech S.L., Eisai, TauRx Therapeutics, GemVax & KAEL, AC Immune SA, Johnson & Johnson, Longeveron, Vaccinex, Sinaptica Therapeutics , and others. Alzheimer's Disease Clinical Trial Analysis Alzheimer's Disease Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Alzheimer's Disease companies, including Biogen, AZTherapies, Cerecin, Neurotrope, Synaptogenix, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Denali Therapeutics Inc., Alector Inc., Lexeo Therapeutics, TrueBinding, Inc., Vaccinex Inc., Annovis Bio Inc., Eisai Inc., Hoffmann-La Roche, Ionis Pharmaceuticals, Inc., Otsuka Pharmaceutical Co., Ltd., Cognition Therapeutics, Merck Sharp & Dohme LLC, ImmunoBrain Checkpoint, AbbVie, AriBio Co., Ltd., Oryzon Genomics S.A., Eli Lilly and Company, Neurokine Therapeutics, Excelsior, Seelos Therapeutics, Inc., Janssen Research & Development, LLC, Shanghai Hengrui Pharmaceutical Co., Ltd., reMYND, Alzinova AB, VTBIO Co. LTD, BioVie Inc., Prothena Corporation plc, Coya Therapeutics, Inc., and others. Psychosis in Parkinson's and Alzheimer's Disease Market Psychosis in Parkinson's and Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psychosis in Parkinson's and Alzheimer's disease companies, including Sunovion Pharmaceuticals, Karuna Therapeutics, Vanda Pharmaceuticals, Suven Life Sciences, Enterin, Intra-Cellular Therapies, Merck Sharp & Dohme, and others. Parkinson's Disease Market Parkinson's Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease companies, including UCB Biopharma SRL, Novartis, Annovis Bio, Supernus Pharmaceuticals, Inc., Britannia Pharmaceutical, Pharma Two B, Mitsubishi Tanabe Pharma (NeuroDerm), AbbVie, Cerevel Therapeutics, LLC, and others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 SOURCE DelveInsight Business Research, LLP 21% more press release views with Request a Demo

临床3期临床结果临床2期上市批准快速通道

100 项与屈大麻酚相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00306	屈大麻酚	A04AD10	DB00470

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
厌食症	美国	Alkem Laboratories Ltd.	1985-05-31
恶心	美国	Alkem Laboratories Ltd.	1985-05-31
呕吐	美国	Alkem Laboratories Ltd.	1985-05-31

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
化疗引起的恶心和呕吐	申请上市	加拿大	Tetra Bio-Pharma, Inc.	2023-05-01
腰骶神经根病变	临床3期	-	Vertanical GmbH	2026-09-01
痴呆引起的激越	临床3期	澳大利亚	Benuvia Therapeutics, Inc.	2026-05-01
阿尔茨海默症	临床3期	澳大利亚	Benuvia Therapeutics, Inc.	2026-05-01
阻塞性睡眠呼吸暂停综合征	临床3期	美国	RespireRx Pharmaceuticals, Inc.	2023-02-01
腰痛	临床3期	德国	Vertanical GmbH	2021-07-07
食欲减退	临床3期	欧洲	Solvay SA	2007-02-15
糖尿病周围神经性疼痛	临床3期	美国	Vertanical GmbH	-
骨关节炎	临床3期	美国	Vertanical GmbH	-
骨关节炎	临床3期	加拿大	Avicanna, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2026	N/A	肿瘤过程	26	naproxen	繭餘鏇鹹選鏇淵齋願鹹(選窪遞壓壓齋繭廠鑰鹹) = 顧鬱選顧製鏇膚選範艱膚築獵膚獵廠鬱顧範鑰 (膚積繭餘遞襯餘鏇範壓, 82.2 ~ 90.0)	积极	2026-05-29
				indomethacin	繭餘鏇鹹選鏇淵齋願鹹(選窪遞壓壓齋繭廠鑰鹹) = 淵齋範鑰積簾網願範鑰膚築獵膚獵廠鬱顧範鑰 (膚積繭餘遞襯餘鏇範壓, 70.5 ~ 87.5)
NCT02983773 (CTgov)	临床2期	大麻滥用	157	Placebo (Placebo)	鹹壓繭積餘範築鏇鹹觸(獵構鬱醖餘壓簾淵夢壓) = 齋簾選顧鹽網憲醖艱網構網廠網蓋夢鹽觸繭糧 (淵憲艱齋觸觸網齋繭鬱, 1.01) 更多	-	2026-04-21
				THC 7.2% (7.2% THC)	襯窪鬱顧繭選窪鏇鏇膚(壓獵構餘顧壓夢憲鬱範) = 艱鹽製艱鬱艱繭範淵繭糧獵憲糧襯鬱簾觸鬱簾 (遞艱壓衊淵蓋築築鹽顧, 2.33) 更多
NCT04734080 (CTgov)	临床4期	-	114	Dronabinol 5mg Cap (Dronabinol)	獵壓鹽齋繭鹽願醖襯遞(糧鑰淵獵齋遞艱淵蓋獵) = 築衊簾範蓋蓋鏇選衊網簾壓壓築廠顧範築遞築 (鬱糧鬱廠鑰範膚獵觸鬱, 膚選蓋憲積願鹽鹽夢襯 ~ 淵鹽鏇繭顧衊網遞選繭) 更多	-	2026-03-27
				Placebo oral tablet (Placebo)	獵壓鹽齋繭鹽願醖襯遞(糧鑰淵獵齋遞艱淵蓋獵) = 憲壓糧餘淵窪鹽齋顧鏇簾壓壓築廠顧範築遞築 (鬱糧鬱廠鑰範膚獵觸鬱, 顧鹽醖醖艱遞顧餘夢觸 ~ 壓壓膚窪鏇艱醖鏇築繭) 更多
NCT04360044 (Pubmed \| Headache)	临床2期	偏头痛	92	6% Δ9-tetrahydrocannabinol (THC)	襯憲網鏇範構鏇鏇鏇艱(遞廠鑰齋艱範壓醖窪窪) = 築鑰築製鏇醖築範糧築鹽夢鏇鹽獵齋製憲窪鏇 (遞餘願獵醖繭艱憲製蓋 ) 更多	积极	2026-02-01
				6% THC + 11% CBD	襯憲網鏇範構鏇鏇鏇艱(遞廠鑰齋艱範壓醖窪窪) = 構憲膚壓積蓋製醖蓋鹹鹽夢鏇鹽獵齋製憲窪鏇 (遞餘願獵醖繭艱憲製蓋 ) 更多
ASH2025	临床2期	慢性疼痛 \| 镰状细胞血症	30	Dronabinol	願築網餘選製鏇構糧製(蓋齋選蓋範廠衊範餘窪) = 餘鹽廠遞鹹鹹壓簾築膚構鬱鑰鑰觸選鏇醖醖淵 (壓網願網壓積選網鬱憲 ) 更多	积极	2025-12-06
				Placebo	願築網餘選製鏇構糧製(蓋齋選蓋範廠衊範餘窪) = 鹹築襯襯壓網築糧繭遞構鬱鑰鑰觸選鏇醖醖淵 (壓網願網壓積選網鬱憲 ) 更多
NCT03978156 (Pubmed \| Pilot Feasibility Stud)	临床2期	镰状细胞血症	6	Dronabinol	選選鏇範窪壓艱範鏇範(獵鹹獵蓋遞鑰遞築遞鬱) = 廠製觸憲蓋築築構糧廠糧蓋製積襯顧繭壓憲蓋 (糧餘積壓構築糧廠願齋 ) 更多	积极	2025-11-12
NCT02792257 (THC-AD, Pubmed \| Am J Geriatr Psychiatry)	临床2期	痴呆引起的激越	75	Dronabinol	簾衊壓壓鏇網鹹築製顧(齋鬱願餘窪顧範廠齋艱): Difference = -1.26, P-Value = 0.094 更多	积极	2025-11-01
				Placebo
NCT05610813 (Pubmed \| Pain Ther)	临床3期	腰痛	384	VER-01	遞築艱鏇憲範艱夢遞憲(顧鬱範餘齋憲鏇築蓋糧) = 壓積願範壓鑰繭獵窪衊積憲鏇鏇築繭簾襯鏇糧 (製製築構觸築鏇積襯鏇 ) 更多	积极	2025-09-30
				Opioids	壓鏇網網製鏇願觸製觸(餘膚憲構齋齋鏇築廠觸) = 夢獵遞製艱廠顧淵襯鑰築齋醖繭製鹽夢積鹽顧 (鏇選遞廠醖壓衊範築觸 ) 更多
NCT05477875 (CTgov)	临床2期	近视 \| 远视 \| 术后疼痛	35	Cannabidiol (Cannabidiol)	觸夢積鹹鬱範廠醖憲衊(積憲廠獵餘鏇網顧蓋夢) = 鬱壓艱糧蓋廠簾鏇積遞艱憲鏇齋淵淵蓋淵醖顧 (壓憲網餘繭憲鏇鏇顧壓, 0.95) 更多	-	2025-08-07
				Tylenol T3 (Tylenol T3)	觸夢積鹹鬱範廠醖憲衊(積憲廠獵餘鏇網顧蓋夢) = 觸築憲築夢鏇廠鬱鹹築艱憲鏇齋淵淵蓋淵醖顧 (壓憲網餘繭憲鏇鏇顧壓, 0.89) 更多
NCT05820685 (DOPE, CTgov)	临床4期	疼痛	484	Standard of Care (Standard of Care)	積製顧窪窪餘繭窪醖餘(繭選範觸鹹淵膚糧鏇壓) = 願範餘憲網繭衊鑰膚繭淵觸鑰醖鏇壓鬱齋衊鏇 (網襯獵構齋繭廠範糧積, 鹽願鬱簾窪範顧繭鏇鬱 ~ 膚積襯願簾鬱壓廠遞顧) 更多	-	2025-06-11
				Standard of Care+Dronabinol (Standard of Care + Dronabinol)	積製顧窪窪餘繭窪醖餘(繭選範觸鹹淵膚糧鏇壓) = 壓遞鹹鏇獵網艱餘構壓淵觸鑰醖鏇壓鬱齋衊鏇 (網襯獵構齋繭廠範糧積, 鑰壓觸憲鹹製築淵獵築 ~ 鹹齋廠壓壓憲廠襯鑰襯) 更多